Antifungal susceptibility of Candida isolates at one institution.

Species distribution and antifungal susceptibility of Candida isolates at one institution were evaluated. Detection rates of fungi were examined for 5 years between 2007 and 2011. Sensitivities of fungi to amphotericin B, flucytosine, fluconazole, micafungin, itraconazole, and voriconazole were evaluated in blood culture-positive patients. A total of 3,832 fungal isolates were detected, including Candida albicans 66.5%, Candida glabrata 20.3%, Candida parapsilosis 6.2%, Candida tropicalis 5.5%, and others 1.5%. Candidemia was diagnosed in 131 patients, and C. albicans, C. parapsilosis, C. glabrata, C. tropicalis, and others were present in 42.0%, 27.5%, 16.0%, 8.4%, and 6.1% of these patients, respectively. Voriconazole had the lowest MIC90s against C. albicans and C. parapsilosis (0.015 and 0.25). Micafungin had a low MIC90 against C. glabrata and C. tropicalis. C. albicans was the most common fungus in patients with candidemia. Voriconazole and micafungin were effective against C. albicans. Amphotericin B was effective for C. parapsilosis, and micafungin showed good efficacy against C. glabrata and C. tropicalis.

[1]  L. Harrison,et al.  Species Identification and Antifungal Susceptibility Testing of Candida Bloodstream Isolates from Population-Based Surveillance Studies in Two U.S. Cities from 2008 to 2011 , 2012, Journal of Clinical Microbiology.

[2]  J. Guinea,et al.  Epidemiology and Antifungal Susceptibility of Bloodstream Fungal Isolates in Pediatric Patients: a Spanish Multicenter Prospective Survey , 2011, Journal of Clinical Microbiology.

[3]  能成 明見.  真菌感染におけるnon-albicans Candida 属の臨床的病原性 , 2009 .

[4]  Y. Myoken.  [Clinical pathogenesis of candidemia caused by non-albicans Candida species]. , 2009, Nihon Ishinkin Gakkai zasshi = Japanese journal of medical mycology.

[5]  Y. Carmeli,et al.  Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  M. Libman,et al.  Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005. , 2008, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[7]  J. Sobel.  The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia , 2007 .

[8]  M. Desnos-Ollivier,et al.  Acquired resistance to echinocandins in Candida albicans: case report and review. , 2007, The Journal of antimicrobial chemotherapy.

[9]  J. Sobel.  The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia , 2006, Current infectious disease reports.

[10]  M. Pfaller,et al.  Global Surveillance of In Vitro Activity of Micafungin against Candida: a Comparison with Caspofungin by CLSI-Recommended Methods , 2006, Journal of Clinical Microbiology.

[11]  S. Ichiyama,et al.  Improved Clinical Outcome of Patients With Candida Bloodstream Infections Through Direct Consultation by Infectious Diseases Physicians in a Japanese University Hospital , 2006, Infection Control & Hospital Epidemiology.

[12]  J. Staab,et al.  Emergence of a Candida krusei Isolate with Reduced Susceptibility to Caspofungin during Therapy , 2006, Antimicrobial Agents and Chemotherapy.

[13]  M. Arendrup,et al.  Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  M. Pfaller,et al.  In Vitro Susceptibilities of Clinical Isolates of Candida Species, Cryptococcus neoformans, and Aspergillus Species to Itraconazole: Global Survey of 9,359 Isolates Tested by Clinical and Laboratory Standards Institute Broth Microdilution Methods , 2005, Journal of Clinical Microbiology.

[15]  J. Vazquez,et al.  Multiechinocandin- and Multiazole-Resistant Candida parapsilosis Isolates Serially Obtained during Therapy for Prosthetic Valve Endocarditis , 2005, Antimicrobial Agents and Chemotherapy.

[16]  A. Tortorano,et al.  Candidosis in the intensive care unit: a 20-year survey. , 2004, The Journal of hospital infection.

[17]  S. Ichiyama,et al.  National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. , 2004, The Journal of antimicrobial chemotherapy.

[18]  J. Cleary,et al.  Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States , 2003, Antimicrobial Agents and Chemotherapy.

[19]  L. Baddour,et al.  Candida lusitaniae infections in the era of fluconazole availability. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  I. Raad,et al.  Candida lusitaniae: a cause of breakthrough fungemia in cancer patients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.